| Investment Objective The scheme shall seek to generate long-term capital appreciation by investing in units of debt oriented mutual fund schemes and arbitrage mutual fund schemes. However, there is no assurance or guarantee that the investment objective of the scheme will be achieved. |
|
| Date of inception/allotment |
4th April, 2025 |
| Fund Manager |
Mr. Anurag Mittal - B.Com, Master of Science, Chartered Account Managing the scheme Since Inception Total Exp: 15 Yrs |
| Fund AUM/Folio as on 31st July, 2026 |
Fund Size Monthly Average : 184.90 Crore Closing AUM : 185.30 Crore No. of Folios : 2,583 |
| High/Low NAV in the month |
High Growth Option : 10.7962 Low Growth Option : 10.7644 |
Month-end Total Expense Ratio (%)** |
Regular : 0.56 Direct : 0.22 *For detailed YTD Total Expense Ratio refer to Click Here |
Minimum Investment Amount |
Minimum initial investment amount is 1,000/- and in multiples of 1/- thereafter with no upper limit. |
Plans/Options (Regular / Direct) |
Growth Option |
Load Structure |
Entry Load # : Nil (Not Applicable as per SEBI guidelines) Exit Load : Nil |
NAV per unit as on 31st July, 2026 |
Regular Growth Option : 10.7962 Direct Growth Option : 10.8464 |
Benchmark Index |
60% CRISIL Short Term Bond Fund Index + 40% Nifty 50 Arbitrage TRI |
# In terms of provision no. 11.7.1 of para 11.7 under Chapter 11 of SEBI Master Circular for Mutual Funds no entry load will be charged by the Scheme to the investor
|
Equity
|
% of NAV
|
| UTI Corporate Bond Fund- Direct Growth | 61.62 |
| UTI Arbitrage Fund-Direct Growth | 35.79 |
| Treps Maturing On 03.08.2026 | 2.69 |
| Net Current Assets | -0.11 |
| Total | 100.00 |
| Healthcare | 90% |
| Financial Services | 10% |
| Fund Performance Vs Benchmark (CAGR) as on 31st July, 2026 Growth of 10000 |
||||||
| Period | NAV Growth (%) |
60% CRISIL Short Term Bond Fund Index + 40% Nifty 50 Arbitrage TRI (%) |
Nifty 50 TRI (%) |
NAV Growth () |
60% CRISIL Short Term Bond Fund Index + 40% Nifty 50 Arbitrage TRI () |
Nifty 50 TRI () |
| 1 Year | 5.39 | 4.99 | 4.21 | 10,539 | 10,499 | 10,421 |
| SI* | 5.96 | 5.43 | 4.92 | 10,796 | 10,725 | 10,656 |
TRI - Total Return Index. Past performance may or may not be sustained in future. Different plans shall have a different expense structure. @ 60% CRISIL Short Term Bond Fund Index + 40% Nifty 50 Arbitrage TRI. The performance details provided herein are of regular plan (growth Option). Returns less than 1 year are Simple Annualized Growth rate. Returns greater than 1 year period are Compound Annual Growth Rate (CAGR). Inception of UTI Income Plus Arbitrage Active Fund of Fund is April 4, 2025. Date of allotment in the scheme/plan has been considered for inception date. The Scheme is currently managed by Mr. Anurag Mittal since May 2025. Period for which scheme’s performance has been provided is computed basis last day of the month-end preceding the date of advertisement. In case, the start/end date of the concerned period is a non-business day, the NAV of the previous date is considered for computation of returns. Load is not taken into consideration for computation of performance.
| Period | |||||||
|
Investment Amount ()
|
Fund Value
() |
Benchmark@
() |
Nifty 50 TRI ()
|
Yield (%) Fund
|
Yield (%)
Benchmark@ |
Yield (%)
Nifty 50 TRI |
|
| 1 Y | 1,20,000 | 1,23,775 | 1,23,319 | 1,19,609 | 5.91 | 5.19 | -0.61 |
| SI | 1,60,000 | 1,66,427 | 1,65,837 | 1,60,336 | 5.72 | 5.20 | 0.30 |
Note: Systematic Investment Plan (SIP) returns are worked out assuming investment of 10,000/- every month at NAV per unit of the scheme as on the first working day for the respective time periods. The loads have not been taken into account. Past performance may or may not be sustained in future.
@ 60% CRISIL Short Term Bond Fund Index + 40% Nifty 50 Arbitrage TRI
This product is suitable for investors who are seeking*:
- Long term capital appreciation
- Investments in units of debt oriented mutual fund schemes and arbitrage mutual fund
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.